Cross-border startup Adcentrx Therapeutics Inc., with operations in San Diego and soon in Shanghai, secured $50 million in a series A financing round led by CBC Group to establish its presence in the antibody-drug conjugate (ADC) space.
DUBLIN – Danish startup Cytoki Pharma ApS raised $45 million in a series A round to take forward an engineered, long-acting version of interleukin-22 (lipidated IL-22), for development in inflammatory bowel syndrome (IBD).
LONDON – Cell transdifferentiation specialist Mogrify Ltd. has raised $17 million in the second close its series A, taking the round to $33 million and enabling the company to progress three cell therapy programs to the clinic.
Onlume Inc. has secured $7 million in a series A round led by Cambridge Investment Group. Other investors participating in the round included WARF Ventures (Wisconsin Alumni Research Foundation) and Wisconsin Investment Partners. The proceeds will support the commercial launch of the company’s FDA-cleared fluorescence-guided surgery (FGS) imaging system.
Capsida Biotherapeutics Inc., a gene therapy startup focused on advanced capsid engineering to generate tissue-selective vectors, emerged from stealth with $50 million in series A funding and another $90 million in cash from a strategic collaboration and option agreement in neurodegenerative disease with Abbvie Inc.
Cross-border startup Adcentrx Therapeutics Inc., with operations in San Diego and soon in Shanghai, secured $50 million in a series A financing round led by CBC Group to establish its presence in the antibody-drug conjugate (ADC) space.
Stuart Therapeutics Inc., a company developing peptide therapeutics for ophthalmic disease, has completed an $11 million series A financing led by Infocus Capital Partners, an ophthalmology-focused life sciences venture capital fund, with significant participation by the Wisconsin Alumni Research Foundation, Mimo Capital and Biobrit.
LONDON – Adaptate Biotherapeutics Ltd. has raised $18 million in the second close of its series A, bringing the total for the round to $34 million and providing the means to accelerate development of a portfolio of antibodies targeting tissue-resident gamma delta T cells.
LONDON – Antibody prospecting specialist Alchemab Therapeutics Ltd. has raised £60 million (US$82.7 million) in a series A round, to take programs in neurodegenerative diseases and cancer into the clinic.
HONG KONG – Onquality Pharmaceuticals LLC raised an additional $20 million from a series A+ financing round, bringing its amount of capital raised to $35 million.
RSS
